Biotech Values

[flatlander_60048]

Liquid Biopsy

I don't necessarily disagree about the competition in the liquid biopsy arena. I invested in BCART:XBRU (getting shelled today) because I'd rather own a disruptive technology provider in this area. They have rolled out on a worldwide basis an IVD platform that allows the results of liquid or solid biopsies to be available in a couple hours rather than 3 weeks. Validation studies are indicating excellent concordance with the reference methods most commonly utilized. The fact that it reduces costs, space needs, technician time and allows treatment to begin much sooner differentiates Idylla from others offering liquid or solid biopsy test methods.

I exited GHDX after it ran up 120% following the Tailor X ASCO results. Most of that money went into BCART since GHDX is migrating the OncoDx Breast assay to BCART'S Idylla, it makes no sense for one to run up on optimism without their partner running. GHDX recently indicated they are set to roll out OncoDx in Europe on the Idylla platform next year. I suspect now that Idylla has launched in the U.S. that they will follow it up with an IPO, here. The GH ipo shows the extent to which valuations are inflated in the U.S.

Regards FL